Noninvasive methods for the early detection of tumor onset and progression in rodent liver would be of high value for pharmaceutical and chemical industry and would, at the same time, foster one of the 3 Rs (replacement, reduction, refinement) by reducing the number of animals in the bioassay. We have induced liver tumors in mice by single injection of diethylnitrosamine (DEN) either in 2-week-(experiment 1) or 6-week-old (experiment 2) male C3H mice. In the latter, mice were also chronically treated with 0.05% phenobarbital in diet according to an initiation/ promotion protocol. Starting at 16 weeks after DEN injection (18 weeks after DEN in experiment 2), mice were routinely scanned by noninvasive magnetic resonance imaging (MRI) using a T2-weighted 3D sequence in regular intervals. Liver tumors became detectable in both experiments when they exceeded a diameter of 1 mm. Exponential increases in total tumor volume per liver were observed in both experiments. The onset of tumor development was similar with respect to DEN treatment. Although mice in experiment 1 had developed a mean total tumor volume of 100 mm 3 approximately 24 weeks after DEN, it took~4 weeks longer to reach this tumor mass in experiment 2. Determination of time-dependent growth of individual tumors demonstrated strong tumor heterogeneity. In vivo MRI data were further correlated with tumor histology. The phenotype of tumors differed strongly between the two experiments, but our results demonstrate that tumors can be reliably detected by MRI when they exceed a certain size independent of their phenotype.
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Noninvasive imaging technologies in clinical diagnosis and preclinical research have raised cancer detection to a new level as detailed morphological, functional, or molecular information can be collected in vivo with minimal impairment for patients and animals. Among other modalities, positron emission tomography (PET), with its outstanding sensitivity, and magnetic resonance imaging (MRI), providing excellent soft tissue contrast at high resolution, complement X-ray computed tomography (Cherry, 2004; Loudos et al., 2010) . Although image contrast in PET directly depends on the radiotracer used and application mode, in MRI, contrast is generated by tissuespecific differences in the reemission of radiofrequency. These differences can be characterized by proton density, T1 and T2 relaxation time measurements; image contrast is adjusted by applying different weightings of these parameters (van Geuns et al., 1999) . Still, detecting liver tumors in patients or in preclinical mouse models by noninvasive imaging remains challenging as many PET biomarkers, used as imaging probes in clinical diagnosis and basic research, are cleared through the liver yielding a nonspecific signal. In addition, the liver is a highly perfused organ leading to further increased background and thus reduced contrast, specifically if the imaging biomarker has a long blood half-life and high plasma protein binding. PET lacks a liver tumor-specific tracer, even though several are under investigation (Park et al., 2008; Talbot et al., 2010; Yamamoto et al., 2008) . Therefore, MRI utilizing highresolution anatomical images demonstrates currently one of the most efficient ways to detect liver tumors in patients (Outwater, 2010) .
Beside routine clinical diagnosis, the utilization of noninvasive imaging technologies for early detection of tumor formation and progression in liver is of utmost importance for preclinical research to identify unwanted carcinogenic effects of drugs or to monitor therapy response in vivo. Additionally, because liver tumors exhibit a wide range of phenotypes, in vivo profiling is of major interest in the clinics as in some cases, different phenotypes present with a different therapy response and thus with a different long-time prognosis (Dal Bello et al., 2010) .
In preclinical research, many different tumor models are available, and therefore, a comparison of tumor phenotypes aiming at in vivo profiling is possible. Chemically induced mouse liver tumors are frequently mutated in Ha-ras, B-raf, or Ctnnb1, leading to constitutive activation of signaling pathways downstream of the respective regulatory proteins affected by mutation of their genes (Aydinlik et al., 2001; Buchmann et al., 1991; Jaworski et al., 2005) . Although Ctnnb1 mutations are highly prevalent in tumors induced by a treatment regimen including phenobarbital (PB) or a PB-like liver tumor promoter (Aydinlik et al., 2001; Strathmann et al., 2006) , Ha-ras or, alternatively, B-raf mutations are seen in up to 70% of spontaneously occurring liver tumors or in tumors induced solely by exclusive treatment with a genotoxic liver carcinogen-like diethylnitrosamine (DEN) (Buchmann et al., 2008; Jackson et al., 2006) . This work focuses on two experimental mouse liver tumor models, which differ with respect to the genotype and resulting phenotype of tumors induced by the two regimens. The goal of this work was to explore the noninvasive in vivo detection limits of liver tumors by MRI, to track individual tumor growth, and correlate the in vivo MRI studies with immunohistochemistry.
MATERIALS AND METHODS
Animals and treatment. Two experiments were performed, each using six male C3H mice: In experiment 1, 2-week-old mice were injected ip with a single dose of DEN (10 lg/g of body weight). Mice were analyzed by MRI starting at 16 weeks after DEN treatment and were sacrificed at the end of the experiment, 28 weeks after carcinogen treatment.
In experiment 2, tumors were initiated in 6-week-old mice by ip injection of a single dose of DEN (90 lg/g body weight). After a treatment-free interval of 3 weeks, mice were kept on a diet containing 0.05% PB until sacrifice. MRI was started 18 weeks after DEN treatment and mice were sacrificed at the end of the experiment, 33 weeks after carcinogen treatment.
All mice were kept on a 12 h dark/light cycle and had access to food and tap water ad libitum. Animals received humane care and protocols complied with institutional guidelines. Mice were sacrificed between 9 and 11 A.M. to avoid circadian influences. Livers were excised, inspected for macroscopically visible tumors, and the number and sizes of tumors were recorded. Larger liver tumors were excised and immediately frozen in liquid nitrogen. Aliquots of the remaining livers were frozen on blocks of dry ice and stored at À70°C for further analysis.
MRI analysis. For MRI, the animals were anesthetized with 1.5% isoflurane (Vetland, Louisville, KY) evaporated in 0.8 l/min pure oxygen. The anesthesia was induced in an isoflurane/oxygen mixture flooded box and then, although still asleep, the animals were placed in head first prone position on the animal beds, where the nose of the animal was placed inside a cone and the anesthesia was maintained by supplying the isoflurane/oxygen mixture through the cone. Body temperature was stabilized using a heating blanket. MRI was performed on a 7 T dedicated small animal scanner (ClinScan; Bruker BioSpin GmbH, Ettlingen, Germany).
For tumor detection, a respiration triggered T2-weighted 3D turbo spin echo sequence was used (TR/TE 3000/205 ms, voxelsize (0.22 mm) 3 ). The isotropic voxelsize of 0.22 mm in all directions provides a high in plane and across plane resolution. Thereby, the location of one tumor could be defined in all three orientations using specific landmarks, such as major vessels or other tumors. For respiration monitoring, a pressure-sensitive pad was placed on the animal bed directly underneath the animal. The compression and decompression of the pad were measured and the generated signal (SAI Instruments, Stony Brook, NY) was finally fed to the MRI scanner. The average acquisition time was approximately 7 min, depending on the respiration rate of the animal. T2-weighted anatomical imaging was performed approximately once weekly; the exact measurement time points are depicted in the scales of the figures. Tissue T2-relaxation times were measured at the end of the experiments using a multicontrast spin echo sequence (TR 2500 ms, TE n*13.6 ms, n ¼ 1-12, voxelsize 0.18 3 0.18 3 1.0 mm 3 ) and relaxation times were calculated with the Syngo software (Siemens Healthcare, Erlangen, Germany). Anatomical and parametric images were analyzed and tumor volumes were measured with the Inveon Research Workplace software package (Siemens Healthcare).
As lesions have to provide significant contrast to their surrounding background and have to exceed a minimal size of approximately 1 mm to be detectable by MRI, current protocols cannot assess total tumor burden because a certain fraction of tumors might be below the detection limit. Assuming that the tumors increase total liver volume, total tumor burden might alternatively be estimated by monitoring liver growth instead of measuring MRI-detectable tumors directly. For this purpose, liver volumes were measured by MRI initially at 16 weeks post-DEN in group 1 and 18-20 weeks post-DEN in group 2, followed by a second MRI measurement at 28 weeks and 33 weeks post-DEN, respectively. Total tumor volume was then calculated by subtracting early liver volumes from late liver volumes.
Enzyme histochemical and immunohistochemical stainings. Serial sections (10-lm thick) were prepared from snap frozen livers. One section was stained enzyme histochemically for glucose-6-phosphatase (G6Pase) activity (Wachstein and Meisel, 1957) . Immunohistochemical stainings were performed by routine methods as recently described (Hailfinger et al., 2006) using antisera against glutamine synthetase (GS) (rabbit anti-GS,1:1000; Sigma-Aldrich, Taufkirchen, Germany) and E-cadherin (rabbit anti-E-cadherin, 1:50; Cell signaling technology, Beverly, MA), in combination with horseradish peroxidase-conjugated secondary antibodies directed against rabbit immunoglobulins (1:100; Dako, Denmark A/S, Glostrup, Denmark) with 3-amino-9-ethylcarbazole/H 2 O 2 as substrates.
Quantification of tumor response postmortem. Serial sections were prepared keeping a distance of 200 lm between sections and stained for G6Pase activity. The numbers and sizes of enzyme-altered lesions in the G6Pase-stained liver sections (4-12 per animal) were quantified by means of a computer-assisted digitizer system consisting of a microscope (Axio Imager; Carl Zeiss MicroImaging GmbH, Jena, Germany) and a pen display (Cintig 21UX; Wacom Europe GmbH, Krefeld, Germany). Areas of liver sections and of enzyme-altered tumor intersections therein were determined and the area fractions of altered lesions (which are equivalent to the volume fractions) were calculated.
Statistical analysis. For statistical analysis, Student's t-test was applied. Differences were considered as statistically significant when p < 0.05. All quantitative values are reported as mean ± 1 SD.
RESULTS

Magnetic Resonance Analysis
Analysis of the magnetic resonance (MR) images shows that the tumors in both groups appear hyperintense in T2-weighted images compared with healthy liver tissue. Representative images of a mouse with fast tumor progression (mouse 1 of the DEN/PB treatment, experiment 2), longitudinally scanned at 20, 24, 28, and 32 weeks after DEN treatment, are shown in Figure 1 . First tumor lesions with a diameter of~1 mm could be depicted in MR images starting approximately in week 19 after DEN treatment in both experiments. Figure 2 shows the tumor progression over time for mice of both experiments. The data points represent the total liver tumor volumes determined in the individual mice at the indicated time points. Analysis of MRI OF LIVER TUMORS individual tumors shows that overall tumor growth is very heterogeneous in both experiments throughout each individual animal (Fig. 3) . Figure 3A shows the individual tumor volumes of the six mice in experiment 1 over time; each graph represents a single mouse; every data point corresponds to a single tumor. The numbers in boxes are the total number of tumors directly identified by MRI in the livers of the animals. Figure 3B displays the data for animals of experiment 2. It is remarkable that a large number of small lesions were detected throughout the entire time period of the study even though the total tumor volume increased exponentially.
Liver tumors < 1 mm in diameter remain undetected by MRI but contribute to the total tumor burden of the animals. We therefore used a second method to indirectly estimate total liver tumor burden. Given that the size of the liver normally remains approximately constant over time in mice when they have reached adulthood, increase in liver size would be indicative of tumor growth. Subsequently, total tumor volume can be calculated by subtracting the liver volume measured at an early time point (16-20 weeks after DEN) from that measured at the end of the experiment. The results obtained by the two methods aimed to determine total tumor volume are compared in Figure 4 . Assessing the tumor volume by calculating the increase in liver volume provides an estimate of the tumor mass, which is on average four times larger than that obtained by directly measuring the tumor volume. This indicates that a large number of smaller tumor lesions are not detected by MRI but contribute significantly to the total liver mass.
Measurements of T2 relaxation times, as quantifiable tissuespecific MRI properties, were evaluated at 27 weeks post-DEN (experiment 1) and 33 weeks post-DEN (experiment 2) treatment. At these time points, the mean tumor volumes of the animals in both experiments were comparable (experiment 1: tumor volume~397 mm 3 and experiment 2: tumor volumẽ 343 mm 3 ). Although tissue properties change during tumorigenesis, no statistically significant differences in T2 relaxation times between tumor and healthy liver tissue were found in both experiments (Table 1) .
Ex Vivo Morphometric Analysis
Tissue sections were prepared from frozen livers and stained for G6Pase. Tumors were identified in the stained sections by an alteration in G6Pase activity (mostly negative) relative to the surrounding normal liver tissue. As known from previous studies (Stahl et al., 2005) , the phenotype of tumors differed considerably depending on treatment protocol of the animals. In mice treated with DEN only (experiment 1), the tumor lesions were mostly basophilic, positive for E-cadherin, and G6Pase was then used as a general tumor marker to quantify the tumor load in animals of both experiments. G6Pase-altered tumor areas and the areas of the entire tissue sections were morphometrically analyzed using 4-12 sections taken from the frozen livers by keeping a distance of 200 lm between each of the serial sections. The mean area fraction of G6Pase-altered tumors to liver tissue was 31.93 ± 22.89% in DEN-only treated mice, which showed a mean lesion number of 32.33 ± 11.24 lesions/cm 2 of liver tissue. The corresponding values in the DEN/PB-treated mice were 18.50 ± 11.07% and 10.06 ± 2.85 lesions/cm 2 , respectively. For a comparison of the semiquantitative histological results with the MRI results, tumor volumes determined by MRI were related to the corresponding liver volumes (Fig. 6 ). Vice versa, tumor areas determined from the G6Pase-stained tissue sections were related to the total area of the corresponding tissue sections. Both MRI methods provide reasonable correlations with relative tumor area of G6Pase staining. The relative tumor burden calculated from MRI data via liver growth (Fig. 6A) is slightly larger than the relative tumor area determined in G6Pase staining, especially for experiment 1. In Figure 6B , directly measured tumor volumes are plotted against relative tumor area determined in G6Pase staining. MRI data seem to underestimate the histological results by a factor of 4 on average.
DISCUSSION
In Vivo MRI Examinations
The primary goal of this study was to investigate the in vivo detection limits of chemically induced mouse liver tumors by noninvasive MRI. The results of this work provide a basis for further studies, potentially aiming at in vivo tumor phenotyping, monitoring of disease progression, and developing novel therapeutic strategies. In our experimental setup, we could reduce the detection limit for tumors as compared with Freimuth et al. (2010) as our high-resolution scanning protocol allows tumor detection and monitoring of individual lesion progression in the whole liver starting with a minimum size of approximately 1 mm in diameter. Additionally, the soft tissue contrast in T2-weighted MR images was sufficiently high in both animal models to reliably detect the tumors without the use of a contrast agent. Pilot studies in our lab indicate that the MRI OF LIVER TUMORS use of contrast agents in our setup does not increase the detectability of tumors in these mouse models, as the tumors can already be distinguished from healthy liver by their inherent soft tissue contrast. This simplifies the experimental setup and, even more importantly, circumvents the application of an exogenous compound, which might potentially impact the animals' physiology, especially in longitudinal studies. On the other hand, dynamic contrast enhanced MRI, including kinetic modeling, can provide additional information on tumor status or phenotype (Metz et al., 2010; Rosen and Schnall, 2007) and also improve tumor detection in clinical diagnosis (Outwater, 2010) . This might specifically apply when combined PET/MRI systems and tumor-specific PET tracer are available (Judenhofer et al., 2008; Schlemmer et al., 2008) .
However, the enrichment of MR contrast agent in tumor lesions strongly depends on tumor vascularization and vessel permeability, which is tumor phenotype specific. Our attempts to distinguish between tumor phenotypes by assessing possible differences in their T2 relaxation times were not successful as there were no significant differences in the T2 relaxation times between tumors from mice of both experiments and the surrounding normal liver tissue. This contrasts with results from Gambarota et al. (2004) , where colon cancer metastases in the rat liver were examined. Apparently, colon cancer metastases in liver can be distinguished from the primary tumors, whereas the different phenotypes of the liver tumors investigated in this paper cannot be distinguished.
Comparison With Histology
In oncological research, histology represents the gold standard in tumor detection as tissue alterations as small as a few cells may already be identified. Major drawbacks, however, are the tremendous effort that is necessary to analyze whole organs and the fact that longitudinal monitoring in individual animals is not possible. Hence, histological information is usually local information at a single time point, which does not necessarily account for the whole organ nor does it allow for monitoring of disease progression. Nevertheless, given an approximately homogenous distribution of tumors throughout the liver, a rough estimation of tumor number and size is possible by histological evaluation of a small number of representative liver sections. However, this procedure is clearly biased because a homogeneous distribution of tumors throughout the liver is rather unlikely. Therefore, one goal of this work was the noninvasive in vivo evaluation of Notes. The tissue-specific T2 relaxation time was measured for tumors and liver tissue in both experiments at time points providing comparable total tumor volume (27 weeks post-DEN treatment in experiment 1; 33 weeks post-DEN treatment in experiment 2). Evaluation using the Student's t-test did not show statistically significant differences between T2 relaxation times of tumors and liver in both experiments. 56 tumor burden in mouse liver by MRI. We evaluated two different MRI-based approaches to quantify tumor burden and compared the results quantitatively with those from histology.
At first, we approximated the total tumor burden by evaluating the hyperintense lesions in the liver. This is a very time-consuming procedure, especially at later stages, where the number of lesions is large. Additionally, merging or regression of small tumors may also occur, resulting in fluctuations of total tumor numbers. This quantification approach is also prone to errors as small lesions may easily be overseen, especially in noisy images. The total tumor volume is systematically underestimated if based on MRI-visible tumors, as even in our dedicated preclinical setup with a voxelsize of approximately 0.01 mm 3 , small tumors below 1 mm in diameter remain invisible for direct measurements. Larger tumors that do not appear hyperintense against healthy liver by their inherent soft tissue contrast may also lead to a further underestimation of total tumor burden.
In our second approach, total tumor burden was calculated by subtracting the total liver volume measured by MRI at an early time point of the experiment from that observed weeks later during tumorigenesis. This approach is based on the assumption that an increase in liver size over time is solely due to an increase in tumor burden. However, this indirect estimation of tumor burden also has its limitations. First, there may be some tumors already present but occult because of their small size during the first measurement of liver size, which will lead to an underestimation of the total tumor burden. The impact of this error may be small, however, as our data indicate a slow growth of the tumors during the initial phases after their induction. Those present at the first size measurement point were all < 1 mm in diameter, thus below the detection limit of our MRI technology. Another concern is that there may be some tumor-independent increase in liver size with an increase in animal age, which is neglected in this calculation because we have to assume that the liver volume is physiologically stable at 18 weeks of age and thereafter. Another point is that PB is a liver-enlarging drug in rodents. However, this drug-mediated increase in liver size occurs shortly after administration of the treatment and there is no further increase in size upon chronic exposure (Schulte-Hermann, 1974) . Because the first time point of determination of liver sizes was 9 weeks after start of PB treatment in experiment 2, we expect that subsequent changes in liver size reflect changes in tumor burden rather than changes mediated by PB treatment. Nevertheless, the issues mentioned above might result in some overestimation of total tumor burden, which may partly explain the difference between MRI-detectable tumor volume and tumor volume calculated from the difference in total liver size as measured early and late in the experiments.
Another uncertainty may be given by the fact that the liver volumes are sometimes assessed from noisy images, introducing some bias. However, from our experience, even with strongly reduced image quality, liver volumes can be measured with reasonable accuracy. Given all these uncertainties, it is noteworthy that the total tumor volumes estimated indirectly from the changes in liver size over time (MRI data) correlate well with the relative tumor areas determined postmortem from the histological liver slides and even better than the total tumor volumes estimated directly from the MRI data.
One of the interesting findings in our study was the extremely strong heterogeneity in growth behavior between individual tumors that was observed in both studies. This result is in good agreement with findings of an earlier study conducted by one of our groups, where liver tumors from DEN-only treated mice were three dimensionally reconstructed from stained serial liver sections (Bauer-Hofmann et al., 1992) . For unknown reasons, some of the tumors (the minority) have an enormous growth potential, whereas others, induced by DEN at the same initial time point, appear to stay small throughout the entire experiment. Interestingly, this also holds true for experiment 2, where PB was used as a tumor promoter, suggesting that a considerable number of tumors induced by DEN was refractory to the growth-stimulatory activity of the tumor promoter. 
MRI OF LIVER TUMORS
This is, to our knowledge, the first study utilizing highresolution MRI technology for an analysis of time-dependent tumor growth in the mouse liver, providing a comparison between T2-weighted MRI and histology and limitations of lesion detectability. Other studies usually aimed to visualize larger tumors only and did not provide a quantitative assessment of detectability (Deane et al., 2004; Griffitts et al., 2009; Lewis et al., 2005; Mutel et al., 2011; Thomas et al., 2003; Zender et al., 2002) . Because of the noninvasive nature of this type of analysis, each of the experimental animals could be monitored at several different time points after induction of the tumors, thus strongly reducing the number of animals required for this type of experiment. This is an important step in the direction of the 3 Rs (replacement, reduction, and refinement). The early and reliable detection of liver tumors by noninvasive MRI is a major step forward in toxicology and the underlying methodology may soon find its way into routine preclinical research because a positive bioassay elicited by promotion of tumor development in rodent liver occasionally occurs as an unwanted side effect during drug development. Further studies are planned, using PET tracers able to detect alterations in the intermediary metabolism of tumor cells as well as mice genetically engineered to express pathway-specific reporters, which can be monitored by PET. These systems employing a combined MRI/PET analysis (Judenhofer et al., 2008) may then allow the noninvasive phenotypic characterization of spontaneous and chemically induced liver tumors. 
